Antihypertensive effects of the hydroethanol extract of Senecio serratuloides DC in rats
- Tata, Charlotte Mungho, Sewani-Rusike, Constance Rufaro, Oyedeji, Opeoluwa Oyehan, Gwebu, Ephraim Tobela, Mahlakata, Fikile, Nkeh-Chungag, Benedicta Ngwenchi
- Authors: Tata, Charlotte Mungho , Sewani-Rusike, Constance Rufaro , Oyedeji, Opeoluwa Oyehan , Gwebu, Ephraim Tobela , Mahlakata, Fikile , Nkeh-Chungag, Benedicta Ngwenchi
- Date: 2019
- Subjects: South Africa Hypertension Computer File
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/11260/5847 , vital:44656 , https://doi.org/10.1186/s12906-019-2463-2
- Description: Senecio serratuloides DC is used in folk medicine for treating hypertension, skin disorders, internal and external sores, rashes, burns and wounds. This study aimed at investigating the antihypertensive effects of the hydroethanol extract of S. serratuloides (HESS) in N-Nitro-L-arginine methyl ester (L-NAME) induced hypertension in rats. Methods: Acute toxicity of HESS was first determined to provide guidance on doses to be used in this study. Lorke’s method was used to determine safety of the extract in mice. Female Wistar rats were treated orally once daily with L-NAME (40 mg/kg) for 4 weeks and then concomitantly with L-NAME (20 mg/kg) and plant extract (150 and 300 mg/kg), captopril (20 mg/kg) or saline as per assigned group for 2 weeks followed by a 2-week period of assigned treatments only. Blood pressure was monitored weekly. Lipid profile, nitric oxide, renin and angiotensin II concentrations were determined in serum while mineralocorticoid receptor concentration was quantified in the kidney homogenate. Nitric oxide (NO) concentration was determined in serum and cardiac histology performed. Results HESS was found to be non-toxic, having a LD50 greater than 5000 mg/kg. Blood pressure increased progressively in all animals from the second week of L-NAME treatment. HESS treatment significantly and dose-dependently lowered systolic blood pressure (p less 0.001), diastolic blood pressure (p less 0.01), low density lipoprotein cholesterol (p less 0.01) and triglycerides (p less 0.01). It significantly prevented L-NAME induced decrease in serum angiotensin II (p less 0.01), high density lipoprotein cholesterol (p less 0.001) and serum nitric oxide concentrations (p less 0.001). HESS also significantly (p less 0.01) prevented collagen deposition in cardiac tissue. Conclusion The hydro-ethanol extract of Senecio serratuloides showed antihypertensive, antihyperlipidemic and cardioprotective effects in rats thus confirming its usefulness in traditional antihypertensive therapy and potential for antihypertensive drug development.
- Full Text:
- Date Issued: 2019
- Authors: Tata, Charlotte Mungho , Sewani-Rusike, Constance Rufaro , Oyedeji, Opeoluwa Oyehan , Gwebu, Ephraim Tobela , Mahlakata, Fikile , Nkeh-Chungag, Benedicta Ngwenchi
- Date: 2019
- Subjects: South Africa Hypertension Computer File
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/11260/5847 , vital:44656 , https://doi.org/10.1186/s12906-019-2463-2
- Description: Senecio serratuloides DC is used in folk medicine for treating hypertension, skin disorders, internal and external sores, rashes, burns and wounds. This study aimed at investigating the antihypertensive effects of the hydroethanol extract of S. serratuloides (HESS) in N-Nitro-L-arginine methyl ester (L-NAME) induced hypertension in rats. Methods: Acute toxicity of HESS was first determined to provide guidance on doses to be used in this study. Lorke’s method was used to determine safety of the extract in mice. Female Wistar rats were treated orally once daily with L-NAME (40 mg/kg) for 4 weeks and then concomitantly with L-NAME (20 mg/kg) and plant extract (150 and 300 mg/kg), captopril (20 mg/kg) or saline as per assigned group for 2 weeks followed by a 2-week period of assigned treatments only. Blood pressure was monitored weekly. Lipid profile, nitric oxide, renin and angiotensin II concentrations were determined in serum while mineralocorticoid receptor concentration was quantified in the kidney homogenate. Nitric oxide (NO) concentration was determined in serum and cardiac histology performed. Results HESS was found to be non-toxic, having a LD50 greater than 5000 mg/kg. Blood pressure increased progressively in all animals from the second week of L-NAME treatment. HESS treatment significantly and dose-dependently lowered systolic blood pressure (p less 0.001), diastolic blood pressure (p less 0.01), low density lipoprotein cholesterol (p less 0.01) and triglycerides (p less 0.01). It significantly prevented L-NAME induced decrease in serum angiotensin II (p less 0.01), high density lipoprotein cholesterol (p less 0.001) and serum nitric oxide concentrations (p less 0.001). HESS also significantly (p less 0.01) prevented collagen deposition in cardiac tissue. Conclusion The hydro-ethanol extract of Senecio serratuloides showed antihypertensive, antihyperlipidemic and cardioprotective effects in rats thus confirming its usefulness in traditional antihypertensive therapy and potential for antihypertensive drug development.
- Full Text:
- Date Issued: 2019
Antihypertensive effects of the hydroethanol extract of Senecio serratuloides DC in rats
- Tata, Charlotte Mungho, Sewani-Rusike, Constance Rufaro, Oyedeji, Opeoluwa Oyehan, Gwebu, Ephraim Tobela, Mahlakata, Fikile, Nkeh-Chungag, Benedicta Ngwenchi
- Authors: Tata, Charlotte Mungho , Sewani-Rusike, Constance Rufaro , Oyedeji, Opeoluwa Oyehan , Gwebu, Ephraim Tobela , Mahlakata, Fikile , Nkeh-Chungag, Benedicta Ngwenchi
- Date: 2019
- Subjects: South Africa Hypertension Computer File
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/11260/5842 , vital:44654 , https://doi.org/10.1186/s12906-019-2463-2
- Description: Senecio serratuloides DC is used in folk medicine for treating hypertension, skin disorders, internal and external sores, rashes, burns and wounds. This study aimed at investigating the antihypertensive effects of the hydroethanol extract of S. serratuloides (HESS) in N-Nitro-L-arginine methyl ester (L-NAME) induced hypertension in rats. Methods: Acute toxicity of HESS was first determined to provide guidance on doses to be used in this study. Lorke’s method was used to determine safety of the extract in mice. Female Wistar rats were treated orally once daily with L-NAME (40 mg/kg) for 4 weeks and then concomitantly with L-NAME (20 mg/kg) and plant extract (150 and 300 mg/kg), captopril (20 mg/kg) or saline as per assigned group for 2 weeks followed by a 2-week period of assigned treatments only. Blood pressure was monitored weekly. Lipid profile, nitric oxide, renin and angiotensin II concentrations were determined in serum while mineralocorticoid receptor concentration was quantified in the kidney homogenate. Nitric oxide (NO) concentration was determined in serum and cardiac histology performed. Results HESS was found to be non-toxic, having a LD50 greater than 5000 mg/kg. Blood pressure increased progressively in all animals from the second week of L-NAME treatment. HESS treatment significantly and dose-dependently lowered systolic blood pressure (p less 0.001), diastolic blood pressure (p less 0.01), low density lipoprotein cholesterol (p less 0.01) and triglycerides (p less 0.01). It significantly prevented L-NAME induced decrease in serum angiotensin II (p less 0.01), high density lipoprotein cholesterol (p less 0.001) and serum nitric oxide concentrations (p less 0.001). HESS also significantly (p less 0.01) prevented collagen deposition in cardiac tissue. Conclusion The hydro-ethanol extract of Senecio serratuloides showed antihypertensive, antihyperlipidemic and cardioprotective effects in rats thus confirming its usefulness in traditional antihypertensive therapy and potential for antihypertensive drug development.
- Full Text:
- Date Issued: 2019
- Authors: Tata, Charlotte Mungho , Sewani-Rusike, Constance Rufaro , Oyedeji, Opeoluwa Oyehan , Gwebu, Ephraim Tobela , Mahlakata, Fikile , Nkeh-Chungag, Benedicta Ngwenchi
- Date: 2019
- Subjects: South Africa Hypertension Computer File
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/11260/5842 , vital:44654 , https://doi.org/10.1186/s12906-019-2463-2
- Description: Senecio serratuloides DC is used in folk medicine for treating hypertension, skin disorders, internal and external sores, rashes, burns and wounds. This study aimed at investigating the antihypertensive effects of the hydroethanol extract of S. serratuloides (HESS) in N-Nitro-L-arginine methyl ester (L-NAME) induced hypertension in rats. Methods: Acute toxicity of HESS was first determined to provide guidance on doses to be used in this study. Lorke’s method was used to determine safety of the extract in mice. Female Wistar rats were treated orally once daily with L-NAME (40 mg/kg) for 4 weeks and then concomitantly with L-NAME (20 mg/kg) and plant extract (150 and 300 mg/kg), captopril (20 mg/kg) or saline as per assigned group for 2 weeks followed by a 2-week period of assigned treatments only. Blood pressure was monitored weekly. Lipid profile, nitric oxide, renin and angiotensin II concentrations were determined in serum while mineralocorticoid receptor concentration was quantified in the kidney homogenate. Nitric oxide (NO) concentration was determined in serum and cardiac histology performed. Results HESS was found to be non-toxic, having a LD50 greater than 5000 mg/kg. Blood pressure increased progressively in all animals from the second week of L-NAME treatment. HESS treatment significantly and dose-dependently lowered systolic blood pressure (p less 0.001), diastolic blood pressure (p less 0.01), low density lipoprotein cholesterol (p less 0.01) and triglycerides (p less 0.01). It significantly prevented L-NAME induced decrease in serum angiotensin II (p less 0.01), high density lipoprotein cholesterol (p less 0.001) and serum nitric oxide concentrations (p less 0.001). HESS also significantly (p less 0.01) prevented collagen deposition in cardiac tissue. Conclusion The hydro-ethanol extract of Senecio serratuloides showed antihypertensive, antihyperlipidemic and cardioprotective effects in rats thus confirming its usefulness in traditional antihypertensive therapy and potential for antihypertensive drug development.
- Full Text:
- Date Issued: 2019
Ursolic Acid and its derivatives as bioactive agents
- Mlala, Sithenkosi, Oyedeji, Adebola Omowunmi, Gondwe, Mavuto, Oyedeji, Opeoluwa Oyehan
- Authors: Mlala, Sithenkosi , Oyedeji, Adebola Omowunmi , Gondwe, Mavuto , Oyedeji, Opeoluwa Oyehan
- Date: 2019
- Subjects: Noncommunicable diseases , Pentacyclic triterpenoids , Ursolic acid , Clinical trials
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/11260/1576 , vital:37793 , https://doi.org/10.3390/molecules24152751
- Description: Non-communicable diseases (NCDs) such as cancer, diabetes, and chronic respiratory and cardiovascular diseases continue to be threatening and deadly to human kind. Resistance to and side effects of known drugs for treatment further increase the threat, while at the same time leaving scientists to search for alternative sources from nature, especially from plants. Pentacyclic triterpenoids (PT) from medicinal plants have been identified as one class of secondary metabolites that could play a critical role in the treatment and management of several NCDs. One of such PT is ursolic acid (UA, 3 β-hydroxy-urs-12-en-28-oic acid), which possesses important biological effects, including anti-inflammatory, anticancer, antidiabetic, antioxidant and antibacterial effects, but its bioavailability and solubility limits its clinical application. Mimusops caffra, Ilex paraguarieni, and Glechoma hederacea, have been reported as major sources of UA. The chemistry of UA has been studied extensively based on the literature, with modifications mostly having been made at positions C-3 (hydroxyl), C12-C13 (double bonds) and C-28 (carboxylic acid), leading to several UA derivatives (esters, amides, oxadiazole quinolone, etc.) with enhanced potency, bioavailability and water solubility. This article comprehensively reviews the information that has become available over the last decade with respect to the sources, chemistry, biological potency and clinical trials of UA and its derivatives as potential therapeutic agents, with a focus on addressing NCD.
- Full Text:
- Date Issued: 2019
- Authors: Mlala, Sithenkosi , Oyedeji, Adebola Omowunmi , Gondwe, Mavuto , Oyedeji, Opeoluwa Oyehan
- Date: 2019
- Subjects: Noncommunicable diseases , Pentacyclic triterpenoids , Ursolic acid , Clinical trials
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/11260/1576 , vital:37793 , https://doi.org/10.3390/molecules24152751
- Description: Non-communicable diseases (NCDs) such as cancer, diabetes, and chronic respiratory and cardiovascular diseases continue to be threatening and deadly to human kind. Resistance to and side effects of known drugs for treatment further increase the threat, while at the same time leaving scientists to search for alternative sources from nature, especially from plants. Pentacyclic triterpenoids (PT) from medicinal plants have been identified as one class of secondary metabolites that could play a critical role in the treatment and management of several NCDs. One of such PT is ursolic acid (UA, 3 β-hydroxy-urs-12-en-28-oic acid), which possesses important biological effects, including anti-inflammatory, anticancer, antidiabetic, antioxidant and antibacterial effects, but its bioavailability and solubility limits its clinical application. Mimusops caffra, Ilex paraguarieni, and Glechoma hederacea, have been reported as major sources of UA. The chemistry of UA has been studied extensively based on the literature, with modifications mostly having been made at positions C-3 (hydroxyl), C12-C13 (double bonds) and C-28 (carboxylic acid), leading to several UA derivatives (esters, amides, oxadiazole quinolone, etc.) with enhanced potency, bioavailability and water solubility. This article comprehensively reviews the information that has become available over the last decade with respect to the sources, chemistry, biological potency and clinical trials of UA and its derivatives as potential therapeutic agents, with a focus on addressing NCD.
- Full Text:
- Date Issued: 2019
- «
- ‹
- 1
- ›
- »